Stereotaxis(US:STXS)2025-11-12 14:00Financial Performance - Revenue for Q3 2025 totaled $7.5 million, with system revenue of $1.9 million and recurring revenue of $5.6 million, compared to $4.4 million and $4.8 million in the prior year[4] - Gross margin for Q3 2025 was 55%, with recurring revenue gross margin at 67% and system gross margin at 19%[5] - Operating loss for Q3 2025 was ($6.6) million, compared to ($6.3) million in the previous year, while adjusted operating loss was ($2.5) million, an improvement from ($3.1) million[7] - Total operating expenses for Q3 2025 were $10.7 million, with adjusted operating expenses of $6.6 million, a decrease from $7.2 million in the prior year[6] Cash Position - Cash and cash equivalents as of September 30, 2025, were $10.5 million, with an expected additional $4 million from upcoming financing, totaling $14.5 million[8] Future Outlook - Stereotaxis expects Q4 2025 revenue to exceed $9 million, supporting annual revenue growth of over 20% for 2025[9] Product Developments - Two Genesis robotic systems were ordered by European hospitals, establishing new robotic programs[3] - MAGiC Sweep generated over $300,000 in revenue within the first two months of its launch following FDA clearance[3] - The company received U.S. FDA clearance for the GenesisX robotic system and announced European CE Mark receipt for Synchrony digital cath lab technology[3] Patient Impact - Stereotaxis has treated over 150,000 patients globally, enhancing access to minimally invasive therapy[11]